NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Price, News & Analysis $23.18 +0.67 (+2.98%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$23.18 0.00 (0.00%) As of 10/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Collegium Pharmaceutical Stock (NASDAQ:COLL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get COLL alerts:Sign Up Key Stats Today's Range$23.06▼$24.0450-Day Range$21.53▼$29.4752-Week Range$21.43▼$50.79Volume1.00 million shsAverage Volume817,193 shsMarket Capitalization$754.74 millionP/E Ratio3.22Dividend YieldN/APrice Target$48.71Consensus RatingHold Company Overview Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions. Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation. The company also markets Jornay PM, an extended-release methylphenidate product for attention-deficit hyperactivity disorder. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium primarily serves the U.S. specialty pharmaceutical market. Its growth strategy has included product acquisitions and portfolio expansion, including the acquisition of BioDelivery Sciences International and the purchase of Ironshore Therapeutics, which added Jornay PM to its commercial portfolio.AI Generated. May Contain Errors. Read More Collegium Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreCOLL MarketRank™: 3.819171256225 of 5 starsCollegium Pharmaceutical scored higher than 76% of companies evaluated by MarketBeat, and ranked 147th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingCollegium Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialCollegium Pharmaceutical has a consensus price target of $48.71, representing about 110.2% upside from its current price of $23.18.Amount of Analyst CoverageCollegium Pharmaceutical has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Collegium Pharmaceutical's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth-22.33% Earnings GrowthEarnings for Collegium Pharmaceutical are expected to decrease by -22.33% in the coming year, from $6.18 to $4.80 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is 3.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.88.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is 3.22, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 197.54.Price to Earnings Growth RatioCollegium Pharmaceutical has a PEG Ratio of 0.73. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Collegium Pharmaceutical's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.27% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 6.06.Change versus previous monthShort interest in Collegium Pharmaceutical has recently decreased by 2.79%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.44 News SentimentCollegium Pharmaceutical has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Collegium Pharmaceutical this week, compared to 4 articles on an average week.Search Interest9 people have searched for COLL on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows2 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Insiders1.85% of the stock of Collegium Pharmaceutical is held by insiders.Percentage Held by InstitutionsCollegium Pharmaceutical has minimal institutional ownership at this time.Read more about Collegium Pharmaceutical's insider trading history. Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COLL Stock News HeadlinesCollegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer SaysOctober 9, 2026 | finance.yahoo.comCollegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to "Strong Sell" at Zacks ResearchOctober 8, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Collegium Pharmaceutical, Inc. Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday LifeOctober 6, 2026 | marketscreener.comMCollegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday LifeOctober 6, 2026 | globenewswire.comCollegium Pharmaceutical (NASDAQ:COLL) vs. Sanofi (NASDAQ:SNY) Critical SurveyOctober 6, 2026 | americanbankingnews.comCollegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer SaysSeptember 23, 2026 | finance.yahoo.comOppenheimer initiates coverage of Collegium Pharmaceutical with outperformSeptember 23, 2026 | msn.comSee More Headlines COLL Stock Analysis - Frequently Asked Questions How have COLL shares performed this year? Collegium Pharmaceutical's stock was trading at $46.30 at the beginning of 2026. Since then, COLL stock has decreased by 49.9% and is now trading at $23.18. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its quarterly earnings results on Thursday, August, 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping analysts' consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical's revenue was up 6.3% compared to the same quarter last year. Read the conference call transcript. How will Collegium Pharmaceutical's stock buyback program work? Collegium Pharmaceutical's Board of Directors authorized a stock buyback program on Monday, July 7th 2025, which authorizes the company to buy back $150,000,000 in shares, according to EventVestor. This means that the company could purchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's management believes its shares are undervalued. When did Collegium Pharmaceutical IPO? Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering on Wednesday, May 6th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's top institutional investors include Farther Finance Advisors LLC (0.05%) and State of Alaska Department of Revenue (0.04%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Shirley R Kuhlmann, Gino Santini, David Dieter, Scott Dreyer, Thomas B Smith, Rita J Balice-Gordon, Garen G Bohlin and John Gordon Freund. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ocular Therapeutix (OCUL), Tesla (TSLA), Gilead Sciences (gild), Micron Technology (MU) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings8/06/2026Today10/15/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 COLL's financial health is in the Red zone, according to TradeSmith. COLL has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:COLL CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees423Year Founded2002Price Target and Rating Average Price Target for Collegium Pharmaceutical$48.71 High Price Target$60.00 Low Price Target$43.00 Potential Upside/Downside+110.2%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$1.24 Trailing P/E Ratio3.22 Forward P/E Ratio3.75 P/E Growth0.73Net Income$62.87 million Net Margins5.93% Pretax Margin9.61% Return on Equity91.43% Return on Assets15.57% Debt Debt-to-Equity Ratio3.32 Current Ratio1.03 Quick Ratio0.84 Sales & Book Value Annual Sales$780.57 million Price / Sales0.97 Cash Flow$15.66 per share Price / Cash Flow1.48 Book Value$9.54 per share Price / Book2.43Miscellaneous Outstanding Shares32,560,000Free Float31,954,000Market Cap$754.74 million OptionableOptionable Beta0.73 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:COLL) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredStop picking AI winners. Start collecting every ThursdayOne fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution ...Investors Alley | SponsoredA simple options strategy that changed one trader's pathIan Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...TradeWins | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COLL Stock Alerts